The non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as delavirdine (Rescriptor), loviride, and nevirapine (Viramune) act by binding directly to the reverse transcriptase molecule, inhibiting its activity.
A fourth class of drugs was under clinical trials in 2003. Called fusion inhibitors, they block HIV from fusing with healthy cells. The first to receive FDA approval will likely be a drug called Enfurvitide.
Because HIV mutates readily, the virus can develop resistance
to single drug therapy. However, treatment with drug combinations appears to produce a durable response. Proper treatment appears to slow
the progression of HIV infections and reduce the frequency of opportunistic infections. One of the most notable advances in recent years has
been the success of highly active antiretroviral therapy (HAART). This multidrug approach reduced the risk of opportunistic infections in
persons with HIV/AIDS and slowed the progression of the disease and death. Usually, patients receive triple combination therapy, however
research in 2003 showed a new once-daily regimen of quadruple therapy effective. The combination included adefovir, lamivudine, didanosine,
and efavirenz. In short, the scientific community continues to make rapid advancements in developing and evaluating antiretroviral drug
therapy. It is best to keep well informed and frequently check with a physician.
ARV ™ Antiretroviral Resource Value, All Rights Reserved.